Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes New Extraction of IBEX011, Its Naturally Derived Ibogaine Drug Candidate, and Commences Stability Testing

Rhelion advances IBEX011 to stability testing and settles $100,000 debt with shares.

What the company is saying

Rhelion Life Sciences Corp. (CSE:RHEL, FSE:4YX0, OTCQB:TRUFF) is highlighting two main developments: operational progress on its ibogaine drug candidate IBEX011 and a completed financial settlement. The company states that its subsidiary Filament Health Corp. has finished a new extraction of IBEX011 and will begin stability testing shortly, positioning this as a step toward supplying regulated clinical research. The narrative emphasizes proprietary extraction methods and draws attention to recent U.S. federal policy shifts supporting psychedelic research, including an April 2026 executive order and an October 2026 FDA consultation. The company also details the settlement of $100,000 in debt owed by Filament, satisfied through the issuance of 3,333,333 common shares at a deemed price of $0.03 per share, with a statutory hold period of four months and one day. The announcement underscores Filament's portfolio of 78 issued patents and the use of its psilocybin candidate PEX010 in over 80 research studies worldwide. The tone is factual, with no exaggerated claims about near-term commercialisation or regulatory approval.

What the data suggests

The company has completed a new extraction of IBEX011 and is preparing to start stability testing, which is an early but necessary step before any clinical or commercial use. No data is provided on the results or timeline for stability testing, nor is there evidence of regulatory submissions or approvals for IBEX011. The $100,000 debt settlement was executed through the issuance of 3,333,333 shares at $0.03 each, and these shares are subject to a statutory hold period. Filament's PEX010 is already supporting more than 80 academic and philanthropic studies, and the company holds 78 issued patents across 13 patent families. The operational disclosures are specific, but there are no financial statements, revenue, or cash flow figures included, so the company's broader financial trajectory remains unclear. The announcement provides transparency on the debt settlement but does not indicate any immediate impact on liquidity or operational funding.

Analysis

The announcement is factual and measured, reporting the completion of a new extraction of IBEX011 and the upcoming start of stability testing. The language is restrained, with no exaggerated claims about commercialisation, regulatory approval, or imminent revenue. Forward-looking statements are limited to the expectation of beginning stability testing and the intended purpose of that testing, which is a standard next step in drug development. The financial disclosure is specific to a completed $100,000 debt settlement via share issuance, with no claims about future financial impact or large capital outlays. There is no attempt to overstate the significance of the operational milestone or to imply near-term commercial returns. The data supports the narrative, and there is no evidence of narrative inflation or overstatement.

Risk flags

• ●IBEX011 remains an investigational drug candidate with no regulatory approvals or authorisation for clinical trials, which means there is significant uncertainty regarding its future commercial viability or timeline to market.
• ●The psychedelic sector faces substantial regulatory hurdles, especially in the United States where ibogaine is a Schedule I controlled substance; policy shifts are positive but do not guarantee eventual approval or access.
• ●The company has settled $100,000 in debt through share issuance rather than cash, which may indicate limited liquidity or a preference to conserve cash, and introduces dilution for existing shareholders.

Bottom line

Rhelion is making incremental progress on its ibogaine candidate IBEX011, with stability testing about to begin, but this remains an early-stage milestone with no immediate commercial or clinical impact. The $100,000 debt settlement via share issuance resolves a prior obligation but results in dilution at a low share price of $0.03. Filament's psilocybin candidate PEX010 continues to see broad research use, and the company holds a sizable patent portfolio, but no new revenue or financial performance data is disclosed. Regulatory and commercial pathways for IBEX011 are still highly uncertain, and investors should recognize that operational and financial risks remain elevated. The most actionable takeaway is that Rhelion is moving forward on technical development and managing legacy debt, but near-term catalysts or value inflection points are not present in this update.

Announcement summary

(CSE:RHEL) (FSE:4YX0) (OTCQB:TRUFF) Rhelion Life Sciences Corp. announced that its wholly owned subsidiary, Filament Health Corp., has completed a new extraction of IBEX011, a naturally derived ibogaine drug candidate. The company expects Filament to begin stability testing on the new extract shortly. This follows a September 10, 2026 announcement that Filament had begun planning a stability program for IBEX011. Stability testing is intended to support a shelf life and specification for IBEX011 and its potential future supply to regulated clinical research. IBEX011 is a total alkaloid iboga extract produced using Filament's proprietary extraction, purification, and stabilization methods, the same platform used to produce PEX010. Recent developments in the United States include an April 2026 executive order identifying ibogaine compounds as investigational therapies of interest and directing federal agencies to accelerate psychedelic research and facilitate access pathways for eligible patients. In October 2026, the FDA sought public input on the design and safety considerations of early-phase ibogaine clinical trials. Ibogaine remains a Schedule I controlled substance in the United States and is not approved by the U.S. Food and Drug Administration, Health Canada, or any other regulatory authority for any indication. IBEX011 is an investigational drug candidate and has not been authorized for use in any clinical trial. PEX010, Filament's botanical psilocybin drug candidate, supports more than 80 academic and philanthropic research studies worldwide. PEX010 is available in a standardized dosing range of 1, 5, and 25 mg, with a 0.5 mg dose to follow, and is produced using Filament's proprietary and patented extraction, purification, and stabilization methods. On April 30, 2026, Rhelion completed its previously announced acquisition of Filament, including its lead drug candidate PEX010 and a portfolio of 78 issued patents across 13 patent families. Effective October 26, 2026, Rhelion completed its previously announced settlement of $100,000 of indebtedness owed to an arm's length creditor in connection with a prior obligation of Filament, through the issuance of 3,333,333 common shares of the company at a deemed price of $0.03 per Settlement Share. The Settlement Shares are subject to a statutory hold period of four months and one day from the date of issuance.

Disagree with this article?